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Rationale: Health-related quality of life (HRQL) is an important outcome in drug trials. Little is
known about how the Short Form-36 (SF-36) and Saint George’s Respiratory Questionnaire
(SGRQ) perform in idiopathic pulmonary fibrosis (IPF).
Objectives: To examine the validity of the SF-36 and SGRQ and to determine scores from each
that would constitute a minimum important difference (MID).
Methods: We analyzed data from a recently completed trial that enrolled subjects with well-
defined IPF who completed the SF-36, SGRQ, and Baseline/Transition Dyspnea Index at base-
line and six months. We compared mean changes in HRQL scores between groups of subjects
whose disease severity changed over six months according to clinical anchors (FVC, DLCO,
and dyspnea). We estimated the MID for each domain by using both anchor- and distribu-
tion-based approaches.
Main results: Results supported the validity of the SF-36 and SGRQ for use in longitudinal
studies. Mean changes in domain scores differed significantly between subjects whose clinical
status improved and those whose clinical status declined according to the anchors. MID esti-
mates for the SF-36 ranged from 2e4 points and from 5e8 points for the SGRQ.
Conclusion: In IPF, the SF-36 and SGRQ possess reasonable validity for differentiating subjects
whose disease severity changes over time. More studies are needed to continue the validation
process, to refine estimates of the MIDs for the SF-36 or SGRQ, and to determine if a disease-
specific instrument will perform better than either of these.
ª 2009 Elsevier Ltd. All rights reserved.398-1621.
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HRQL in IPF 297Introduction to generate linear T-score transformations (http://gim.Idiopathic pulmonary fibrosis (IPF) is a progressive inter-
stitial lung disease (ILD) without effective therapy. Patients
with IPF have impaired health-related quality of life (HRQL)
in nearly every domain,1 and dyspnea is one strong driver of
that impairment.2
By quantifying patients’ perceptions,3 HRQL instruments
capture information that physiologic or radiologic measures
do not. Thus, investigators view HRQL as an important
outcome to use when attempting to determine the effec-
tiveness of a particular intervention. In patients with IPF,
the Short Form- (SF-) 36 and Saint George’s Respiratory
Questionnaire (SGRQ) yield scores reflecting impaired
HRQL, and at single time points, their scores correlate with
clinical measures of IPF severity.4 In IPF, what is unknown
about either of them is whether they are responsive to
underlying change in status and whether they can
discriminate between patients whose status over time
improves, remains unchanged, or declines. Also lacking for
IPF is a basic understanding of how to interpret changes in
HRQL scores. Finally, the minimum score change considered
clinically important (i.e., the minimum important differ-
ence or MID) is known for the SF-36 and SGRQ for certain
conditionsdbut not for IPF.
The overarching goal of this study was to advance
understanding and improve interpretation of SF-36 and
SGRQ scores in IPF. The main hypotheses were that scores
would decline in subjects whose disease progressed; that
both the SF-36 and SGRQ could discriminate patients who
improve, remain stable, or decline or over time; and that
we could use both anchor- and distribution-based methods
to establish MID estimates for these instruments in patients
with IPF.Methods
Overview
We used data from a recently completed trial (the Bosentan
Use in ILD-1 or BUILD-1)5 for this retrospective analysis.
Details of the BUILD-1 study have been described previ-
ously.5 Briefly, subjects had very well-defined IPF according
to accepted consensus guidelines.6,7 The SF-36 version 1,
SGRQ, and Baseline/Transition Dyspnea Index (BDI/TDI)
were administered at baseline, six months, and twelve
months. We used baseline and six month data for our study
because this provided us the greatest number of datapoints
with which to perform our analyses.
Assessment tools
The SF-36 is a generic questionnaire with 36 items that
measure functional health and well-being.8 It comprises
eight domains and two psychometrically-established
summary components, each derived from four domain
scores. Domain and summary component scores range from
0e100; higher scores correspond to better health status or
well-being. For each domain and summary component, as
endorsed by SF-36 developers, we used scoring algorithmsmed.ucla.edu/FacultyPages/Hays/util.htm; last accessed
August 1, 2008). Such transformations place scores on
scales with mean scores equal to 50 (and standard devia-
tions of 10). The SGRQ is a self-administered, obstructive
lung disease-specific questionnaire with 50 items
comprising three domains, each scored from 0e100, with
higher scores corresponding to worse HRQL.9 The BDI has
three domains.10 The TDI is a follow-up questionnaire that
asks respondents to rate (from ‘major deterioration’Z3
to ‘major improvement’Zþ3) how dyspnea has changed
over time for each BDI domain; thus, scores for the TDI
range from 9 (largest deterioration) to þ9 (largest
improvement).Statistical analysis
We used baseline values to calculate mean scores, standard
deviations, standard errors of measurement (SEM), and
internal consistency reliability (Cronbach’s alpha11) coeffi-
cients for each instrument. Next, we applied the methods
of Kosinski and colleagues12 and their use of known-groups
validity13 to examine relationships between either SF-36 or
SGRQ scores and FVC, DLCO, and dyspnea, which we will
heretofore refer to as anchors. Excluded from our analyses
were subjects whose FVC, DLCO, TDI, or entire HRQL
questionnaires were missing at either baseline or six
months.
We began the analyses by calculating anchor change
scores. For FVC, we categorized subjects as ‘‘unchanged’’
if the difference in the raw FVC value at month six was
within 7% (inclusive) of the baseline value, as ‘‘changed
minimally’’ if the difference at month six was between 7
and 12% (exclusive) of baseline, and as ’’changed more than
minimally’’ if the difference was 12%. We used the widely
accepted cut-off value of 15% to represent a significant
difference from baseline in DLCO; we elected not to parse
DLCO into more categories because of the greater statis-
tical ‘‘noise’’ in DLCO as compared with FVC, and it is far
less clear to us what the range for a minimum change in
DLCO should be. Thus, we did not use DLCO as an anchor in
the MID analyses (see below). We used TDI scores as an
anchor because dyspnea has been shown to be a strong
influence on HRQL in patients with IPF,2 and attempts have
been made to define the MID for the TDI (at least in pop-
ulations other than IPF14).
Next, we calculated mean SF-36 and SGRQ scores for
subjects within each anchor change category. We used
ANOVAdone for each HRQL domaindto compare contrasts
in mean changes in SF-36 or SGRQ domain scores across
anchor change categories. These models generated F-
statistics; a larger F-statistic connotes a domain that yields
a larger separation between mean HRQL scores across
anchor change categories and/or a smaller within group
variance.
We used Pearson product-moment correlation coeffi-
cients to examine relationships between anchors and HRQL
scores. To derive MID estimates for domains from each
instrument, we used the effect size (ES) and the 1-SEM
criterion15,16 as distribution-based approaches. Although
there is no consensus about how or even whether17 the ES
Table 1 Characteristics of subjects in BUILD-1.
Variablea
Age 65.12 (8.93)
BMI 29.18 (4.31)
Gender M/F 73/27
Smoking status (%)
Non/Current 98/2
Race (%)
Caucasian 92
Black 2
Asian 1
Hispanic 4
Other 1
Baseline FVC L 2.64 (.73)
Baseline FVC% 66.97 (12.17)
Baseline DLCO% 40.98 (10.08)
FVC (%)
Improved 12% 6
Improved 7e12% 8
Unchanged 53
Declined 7e12% 20
Declined 12% 13
DLCO (%)
Improved 15% 10
Unchanged 65
Declined 15% 25
TDI (%)
Improved 4 points 5
Improved 1e3 points 16
Unchanged 38
Declined 1e3 points 24
Declined 4 points 17
a NZ 158 for baseline data and 129 for change data. Data are
presented as means (SD) or percentages.
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consider 0.5 to correspond to the MID,18,19 and that is what
we used here. In the first anchor-based approach, we used
linear regression to examine the relationship between
change in HRQL (dependent variable) and change in the
anchordFVC or TDI score (independent variables).20 We
derived a point estimate for the MID by plugging into these
equations values representing a minimal change (e.g., 10%
for raw FVC [roughly the midpoint of our minimum change
range of 7e12%] and one point for the TDI) in the inde-
pendent variable. In the second anchor-based approach,
we calculated the weighted average of mean change scores
for each HRQL domain for subjects who changed (either
improved or declined) minimally according to the FVC and
TDI anchors. All analyses were performed with SAS version
9.1.3 (SAS Institute Inc., Cary, NC), and p-values < .05 were
considered statistically significant.
Results
Subjects
Demographics, baseline values for FVC and DLCO, and
proportions of subjects who changed according to the
anchors are found in Table 1. Table 2 displays baseline data
for the SF-36 and SGRQ.
Changes in SF-36 and SGRQ
Except for the Symptoms domain for DLCO, mean change
scores from each SGRQ domain differed significantly
between categories of change in each of the three anchors.
Findings were similar for certain SF-36 domains (Table
located in online supplement).
The FVC anchor
For the SF-36, the Physical Functining and Social Func-
tioning domains along with the Physical Component
Summary score (PCS) were most useful (i.e., valid) to
discriminate between all categories of change in the FVC
anchor (Fig. 1). The Role Emotional domain (RE) discrimi-
nated best between the subset of subjects whose FVC
either improved or declined minimally: the difference in RE
change scores between subjects in whom FVC improved by
7e12% and those in whom FVC declined by 7e12% was 1.1
standard deviation units (e.g., the difference between an
increase of 10.6 points for subjects with FVC improvement
7e12% and a decline of 5.3 points for subjects with FVC
decline 7e12% divided by the baseline standard deviation
for RE: 10.6e(5.3)/14.2). For the SGRQ, the Impact
domain discriminated best between all categories of
change in the FVC anchor as well as between subjects
whose FVC either improved or declined minimally: the
difference in Impact change scores between subjects in
whom FVC improved by 7e12% and those in whom FVC
declined by 7e12% was 0.7 standard deviation units (SDU).
The DLCO anchor
For the SF-36, the PCS and RE domains discriminated best
between all categories of change in the DLCO anchor
(Fig. 2A). The difference in RE change scores betweensubjects in whom DLCO improved by>15% and those in
whom DLCO declined by>15% was 0.9 SDU. For the SGRQ,
the Impact domain discriminated best between categories
of change in the DLCO anchor (Fig. 2B). The difference in
Impact change scores between subjects in whom DLCO
improved by>15% and those in whom DLCO declined
by>15% was 0.8 SDU.
The TDI anchor
For the SF-36, the Vitality (VT) and PCS domains discrimi-
nated best between all categories of change in the TDI
anchor. Because of low numbers of subjects with TDI scores
of 1 or 1, for this analysis, we elected to compare differ-
ences in HRQL change scores between subjects with TDI
scores of 2 and those with TDI scores of 2. The VT domain
remained most useful to discriminate between subjects
whose TDI either improved or declined by 2 points: the
difference in VT change scores between subjects in whom
TDI improved by 2 and those in whom TDI declined by 2
points was 1.1 SDU. The SGRQ Impact domain discriminated
best between all categories of change in the TDI anchor
(Fig. 3). For the SGRQ, the Symptoms domain discriminated
Table 2 Baseline data for the SF-36 and SGRQ.
Measure Mean Score SD 95% CI Internal Consisteny Reliabilitya
SF-36 scale
Physical functioning 35.4 10.3 33.7e37.0 .90
Role physical 37.8 11.6 35.9e39.7 .82
Bodily pain 47.6 10.7 45.9e49.3 .67
General health 37.8 9.4 36.3e39.3 .76
Vitality 43.1 9.2 41.6e44.6 .80
Social functioning 44.6 12.3 42.6e46.5 .82
Role emotional 42.7 14.2 40.4e45 .85
Mental health 48.2 10.1 46.5e49.8 .77
Physical health summary 37 10 35.4e38.6 .91
Mental health summary 44.2 10.84\ 42.4e45.9 .89
SGRQ
Symptoms 50.1 21.9 48.2e52.1 .66
Activity 60.6 22.8 58.6e62.7 .84
Impact 33.7 20.6 31.9e35.6 .85
Total 44.8 19.5 43.0e46.5 .91
a Cronbach’s alpha.
HRQL in IPF 299best between subjects whose TDI either improved or
declined by 2 points: the difference in Symptoms change
scores between subjects in whom TDI improved by 2 and
those in whom TDI declined by 2 points was 0.9 SDU.
MID analyses
Correlations between the two anchors used in these anal-
yses and HRQL scores are presented in Table 3. For the SF-
36, distribution-based MID estimates were greater than
anchor-based estimates (Table 4). For a given domain, the
1-SEM and 0.5ES estimates were fairly similar. On balance,
minimally important changes in FVC corresponded to
slightly higher MID estimates than did minimally importantFigure 1 Changes in SF-36 scoreschanges in the TDI anchor. Means of MID estimates for the
SF-36 ranged from 2 for the GH domain to 4 for a number of
domains. As for the SF-36, for the SGRQ, distribution-based
MID estimates were greater than anchor-based estimates.
Grand means of MID estimates for SGRQ domains ranged
from 5 for the Activity domain to 8 for the Symptoms
domain.Discussion
We performed the first systematic examination of the
longitudinal performance of the SF-36 and SGRQ in patientsstratified on changes in FVC%.
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300 J.J. Swigris et al.with IPF. We found subjects whose clinical status changed
most had the greatest changes (in the appropriate direc-
tion) in SF-36 and SGRQ scores; subjects whose clinical
status did not change had essentially no change in HRQLTable 3 Coefficients and p values for correlations between HR
PF RP BP GH VT SF RE MH
FVC% 0.23 0.2 0.04 0.29 0.14 0.04 0.17 0.0
0.004 0.01 0.6 .0004 0.08 0.6 0.04 0.5
TDI 0.38 0.27 0.2 0.3 0.3 0.3 0.13 0.2
<.0001 0.002 0.04 .0007 .0006 .0007 0.1 0.3
Top number in each cell is the pearson product-moment correlation
SF-36: PFZ Physical functioning, RPZ Role physical, BPZ Bodily pa
REZ Role emotional, MHZMental health, PCSZ Physical compone
tomsZ Symptoms component, ActivityZ Activity component, Impacscores; and subjects whose clinical status changed mini-
mally had minimal changes in HRQL scores. We also derived
the first MID estimates for the SF-36 and SGRQ in IPF.
There are no data on the longitudinal performance
characteristics of the SGRQ in IPF. In the only longitudinal
study to examine the SF-36 in IPF,21 Tomioka and colleagues
showed that certain domains discriminated between
subjects whose clinical status had changed according to
pulmonary physiology or peripheral oxygenation. They did
not estimate MIDs for SF-36 domains.
Validation is a process involving testing multiple
hypotheses about an instrument to determine whether it
‘‘behaves’’ as expected of one designed to measure
HRQL,22 and whether its scores can be used confidently
(e.g., to determine whether a therapeutic intervention is
beneficial). Our results support the validity of the SF-36 and
SGRQ for longitudinal use in IPF and allow us to apply
meaning to changes in SF-36 and SGRQ scores. For example,
a group of IPF patients whose SF-36 PCS domaindwhichQL domains and anchors.
PCS MCS Symptoms Activity Impact Total
5 0.24 0.11 0.3 0.31 0.32 0.35
0.003 0.2 0.004 .0001 <.0001 .0001
1 0.35 0.3 0.28 0.39 0.47 0.45
5 <.0001 .0006 0.001 <.0001 <.0001 <.0001
coefficient and the bottom number is the p value.
in, GHZGeneral health, VTZ Vitality, SFZ Social functioning,
nt summary, MCSZMental component summary. SGRQ: Symp-
tZ Impact component.
Table 4 Distribution- and anchor-based estimates for MIDs of the SF-36 and SGRQ.
Measure 1-SEM (.5)ES Regression equations DFVCa DTDIa Mean MID
SF-36 scale
PF 3.2 5.1 DPF[ .7þ .18(DFVC), R2[ 0.1 2.1 2.3 2.9 3
Corresponding to a 10% change in raw FVC,
DPFZ 2.5 (1.1e3.9)
DPF[ 1.1D 1.11(DTDI), R2[ 0.2
Corresponding to a 1 point change in TDI,
DPFZ 2.2 (1.7e2.6)
RP 4.9 5.8 DRP[ 1.7þ .16(DFVC), R2[ 0.02 2.4 2.3 3.7 4
Corresponding to a 10% change in raw FVC,
DRPZ 3.3 (1.3e5.4)
DRP[ 2.1D 1.40(DTDI), R2[ 0.05
Corresponding to a 1 point change in TDI,
DRPZ 3.5 (2.8e4.2)
BP 6.1 5.3 DBP[.2þ .14(DFVC), R2[ 0.04 1.6 1.3 2.6 3
Corresponding to a 10% change in raw FVC,
DBPZ 1.2 (.5 to 3.0)
DBPZ.8þ .63(DTDI), R2[ 0.1
Corresponding to a 1 point change in TDI,
DBPZ.2 (.8 to .4)
GH 4.6 4.7 DGHZ.02þ .07(DFVC), R2[ 0.01 1.2 1.0 2.3 2
Corresponding to a 10% change in raw FVC,
DGHZ .7 (.5 to 1.8)
DGHZ .63þ .92(DTDI), R2[ 0.1
Corresponding to a 1 point change in TDI,
DGHZ 1.6 (1.1e1.9)
VT 4.1 4.6 DVT[ .47þ .16(DFVC), R2[ 0.05 3.7 .3 2.8 3
Corresponding to a 10% change in raw FVC,
DVTZ 2.1 (.8e3.4)
DVTZ .84þ .87(DTDI), R2Z 0.1
Corresponding to a 1 point change in TDI,
DVTZ 1.7 (1.2e2.1)
SF 5.2 6.2 DSFZ 1.3þ .37(DFVC), R2[ 0.1 2.8 1.7 4 4
Corresponding to a 10% change in raw FVC,
DSFZ 5.0 (2.1e7.0)
DSFZ 1.47þ 1.36(DTDI), R2Z 0.1
Corresponding to a 1 point change in TDI,
DSFZ 2.8 (2.2e3.5)
RE 5.5 7.1 DRE[ 1.0D .27(DFVC), R2[ 0.05 6.9 0 4.2 4
Corresponding to a 10% change in raw FVC,
DREZ 3.7 (1.4e6.1)
DRE[ 1.17D .93(DTDI), R2[ 0.05
Corresponding to a 1 point change in TDI,
DREZ 2.1 (1.3e2.9)
MH 4.8 5.0 DMH[ .96D .04(DFVC), R2[ 0.001 1.3 2 2.7 3
Corresponding to a 10% change in raw FVC,
DMHZ 1.3 (.8e2.8)
DMH[ 1.16D .52(DTDI), R2[ 0.02
Corresponding to a 1 point change in TDI,
DMHZ 1.6 (.9e2.2)
PCS 3 5 DPCS[ .91D .19(DFVC), R2[ 0.1 2.2 1.3 2.8 3
Corresponding to a 10% change in raw FVC,
DPCSZ 2.8 (1.5e4.2)
DPCS[ 1.39D 1.31(DTDI), R2[ 0.2
Corresponding to a 1 point change in TDI,
DPCSZ 2.7 (2.3e3.1)
(continued on next page)
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Table 4 (continued)
Measure 1-SEM (.5)ES Regression equations DFVCa DTDIa Mean MID
MCS 3.6 5.4 DMCS[ 1.2D .23(DFVC), R2[ 0.1 3.7 1.7 3.4 3
Corresponding to a 10% change in raw FVC,
DMCSZ 3.5 (2.0e4.9)
DMCS[ 1.47D 1.09(DTDI), R2[ 0.1
Corresponding to a 1 point change in TDI,
DMCSZ 2.5 (2.1e3.1)
SGRQ
Symptoms 12.8 11 DSym[2.4 to .46(DFVC), R2[ 0.1 3.8 11.7 8.4 8
Corresponding to a 10% change in raw FVC,
DSymZ7 (9 to (4.2))
DSym[L2.15e1.66(DTDI), R2[ 0.1
Corresponding to a 1 point change in TDI,
DSymZ3.8 (4.7 to (2.9))
Activity 9.1 11.4 DAct[ .71 to .18(DFVC), R2[ 0.02 4.8 0.6 4.8 5
Corresponding to a 10% change in raw FVC,
DSymZ1.1 (3.6 to .1)
DAct[.1e1.88(DTDI), R2[ 0.2
Corresponding to a 1 point change in TDI,
DActZ1.9 (3.7 to (1.2))
Impact 8 10.3 DImp[4.12 to .54(DFVC), R2[ 0.1 5.8 1.2 7.1 7
Corresponding to a 10% change in raw FVC,
DImpZ9.5 (12 to (7))
DImp[4.63 to 2.89(DTDI), R2[ 0.3
Corresponding to a 1 point change in TDI,
DImpZ7.5 (8.2 to (6.7))
Total 5.9 9.8 DTot[2.6e.41(DFVC), R2[ 0.1 5.4 6 6.6 7
Corresponding to a 10% change in raw FVC,
DTotZ6.7 (8.9e(4.6))
DTot[3.11e2.36(DTDI), R2[ 0.3
Corresponding to a 1 point change in TDI,
DTotZ5.5 (6.1 to (4.8))
SF-36: PFZ Physical functioning, RPZ Role physical, BPZ Bodily pain, GHZGeneral health, VTZ Vitality, SFZ Social functioning,
REZ Role emotional, MHZMental health, PCSZ Physical component summary, MCSZMental component summary.
SGRQ: SymZ Symptoms component, ActZ Activity component, ImpZ Impact component, TotZ Total score.
a Weighted average of subjects improving or declining by the ‘‘minimal’’ value of the anchor. MID estimates for a given domain were
derived from the mean (rounded up) of the six MID estimates for that domain.
302 J.J. Swigris et al.assesses physical healthdscore drops by three points is
likely to have an FVC decline of at least 12% and worsening
dyspnea (three-point decline in TDI).
Discriminating between subjectswho improve or declined
an attribute some label as discriminant validitydis key to the
usefulness of anyHRQL instrument. That all domain scores did
not change to the samedegree (or at all) for certain anchors is
not unexpected and does not detract from the usefulness of
an instrument. As demonstrated by higher F-statistics, the
SGRQ Impacts domain best discriminated between change
categories in each of the three anchors. Among SF-36 scales,
the PCS best discriminated between change categories in two
of the three anchors. This is not surprising, given the greater
impairment in physical domains in IPF and that the PCS inte-
grates the four SF-36 physical health domains.
The recently modified definition of MID is that it is the
smallest difference in a score that informed patients or
proxies perceive as important, either beneficial or harmful,and which would lead the patient or clinician to consider
a change in management.20 There is no one correct way to
estimate the MID; it should be done using multiple
methods.17 There are no published MID estimates for the
SF-36 for IPF or even, to our knowledge, for COPD. Exam-
ining the results of a study by Kosinski and colleagues,12 in
which MIDs for the SF-36 were derived in subjects with
rheumatoid arthritis, gives some perspective to our SF-36
MID estimates: after converting estimates from their study
to norm-based, we found our estimates to be very similar.
Their MID estimate for the PF domain was 3 points versus 3
from this studydfor RP 5 vs. 4, BP 5 vs. 3, GH 1 vs. 2, VT 4
vs.3, SF 4 vs. 4, RE 5 vs. 4, MH 5 vs. 3, PCS 3 vs. 3, MCS 4 vs.
3. These similarities are not surprising: one expects that
a generic instrument (like the SF-36) would behave simi-
larly, no matter the population.
For the SGRQ, our MID estimates were greater than its
widely accepted MID of four pointsdan estimate derived in
HRQL in IPF 303patients with obstructive diseases by using expert opinion
and anchor-based approaches.23 The divergence likely
reflects differences in IPF vs. COPD and the differing
behavior of the SGRQ in each. Recall, the SGRQ is
obstructive diesease-specific, and certain items tap
constructs (e.g, wheezing) not pertinent to IPF patients.
Pulished distribution-based MID estimates for the SGRQ vary
widely, ranging from 1.3 to 8.4 units.23 Our distribution-
based estimates ranged from 6e13.
We chose FVC, DLCO, and dyspnea as anchors because,
in patients with IPF, each is key to tracking clinical status,
and they are commonly used trial outcomes. We considered
a 7e12% change in raw FVC as minimally important,
because this range covers both 7% (recently shown to carry
prognostic significance in IPF24,25) and 10% (a globally
accepted value for significant change and a common
endpoint in clinical trials). In populations other than IPF,
a one-unit change in TDI is the MID,14 so we used it here.
The primary limitation of this study is the relatively small
number of subjects whose pulmonary physiology changed
over time, which left us with imprecise MID estimates.
Unfortunately, patient-report global change scores (where
a subject rates his overall HRQL at present in relation to
baseline, often on a 7-choice Likert scale) were not
collected in the BUILD-1 trial; if they had been collected,
such scores could have been used as an anchor. Some
investigators argue that global change scores make the best
anchors.17 The inclusion criterion that subjects’ baseline
6MWD had to between 150e499 meters means the results of
our analyses may not be translatable to all IPF patients (e.g.,
those in the end stages of the disease who are unable to walk
150meters in sixminutes). The strength of our study is that it
yielded the first-ever estimates of MIDs for the SF-36 and
SGRQ in IPFdresults that could be useful for guiding future
research. In future IPF studies, investigators should perform
confirmatory assessments of validity, responsiveness, and
MIDs for the SF-36 and SGRQ (or any other instrument). Until
a disease-specific instrument is developed and tested,
investigators can confidently administer either or both the
SF-36 and SGRQ in their studiesdand pay close attention to
domains that have been shown to be useful.
In sum, we examined the SF-36 and SGRQ in a longitu-
dinal IPF study and found them to perform reasonably well.
Each possessed validity for discriminating subjects whose
disease status changed by differing degrees over time. We
derived the first estimates of the MIDs for these two
instruments in IPF. More studies are needed to refine these
estimates and further advance our understanding of the
behavior of these instruments in IPF.
Conflict of interest
The work in this manuscript is the original work of the
stated authors. None of the authors has any real or
potential conflicts with information in this manuscript.
Acknowledgments
The authors wish to acknowledge the efforts of all the
personnel at Actelion Pharmaceuticals (trial sponsor) and of
the investigators involved in the BUILD-1 trial: Ishaar Ben-Dov, Charles Chan, Jean-Francois Cordier, James Dauber,
Joao De Andrade, Adaani Frost, Thomas Geiser, Marilyn
Glassberg, Jeffrey Golden, Gary Hunninghake, Sanjay
Kalra, Lisa Lancaster, Robert Levy, Fernando Martinez,
Keith Meyer, Joachim Mueller-Quernheim, Paul Noble,
Christophe Pison, Charles Poirier, Milton Rossman, Paola
Rottoli, Gerd Staehler, Domonique Valeyre, Athol Wells,
Gordon Yung and David Zisman. We also wish to thank Dr.
Diane Fairclough for her comments on a prior version of this
manuscript and Dr. Ron Hays for his availability to answer
questions pertaining to the MID.
Study conceptualization and design: Swigris, Wamboldt
Data collection: Swigris, Brown, Behr, du Bois, King,
Raghu and the BUILD-1 investigators
Statistical analyses: Swigris, Wamboldt
Manuscript preparation and final approval: Swigris,
Brown, Behr, du Bois, King, RaghuSupplementary information
Supplementary data associated with this article can be
found, in the online version, at doi:10.1016/j.rmed.
2009.09.006.
References
1. Swigris JJ, Gould MK, Wilson SR. Health-related quality of life
among patients with idiopathic pulmonary fibrosis. Chest 2005;
127:284e94.
2. Nishiyama O, Taniguchi H, Kondoh Y, et al. Health-related
quality of life in patients with idiopathic pulmonary fibrosis.
What is the main contributing factor? Respir Med 2005;99:
408e14.
3. Abrams D. Analysis of a life-satisfaction index. J Gerontol
1976;24:470.
4. Swigris JJ, KuschnerWG, Jacobs SS,Wilson SR, Gould MK. Health-
related quality of life in patients with idiopathic pulmonary
fibrosis: a systematic review. Thorax 2005;60:588e94.
5. King Jr TE, Behr J, Brown KK, et al. BUILD-1: a randomized
placebo-controlled trial of bosentan in idiopathic pulmonary
fibrosis. Am J Respir Crit Care Med 2008;177:75e81.
6. Joint Statement of the American Thoracic Society and the
European Respiratory Society. Idiopathic pulmonary fibrosis:
diagnosis and treatment. Am J Respir Crit Care Med 2000;161:
646e64.
7. Joint Statement of the American Thoracic Society and Euro-
pean Respiratory Society. American thoracic society/European
respiratory society international multidisciplinary consensus
classification of the idiopathic interstitial pneumonias. Am J
Respir Crit Care Med 2002;165:277e304.
8. Ware Jr J, Sherbourne C, The MOS. 36-item short-form health
survey (SF-36). I. Coceptual framework and item selection.
Med Care 1992;30:473e83.
9. Jones P, Quirk F, Baveystock C. The St. George’s respiratory
questionnaire. Respir Med 1991;85:25e31.
10. Mahler DA, Weinberg DH, Wells CK, Feinstein AR. The
measurement of dyspnea. Contents, interobserver agreement,
and physiologic correlates of two new clinical indexes. Chest
1984;85:751e8.
11. Cronbach L. Coefficient alpha and the internal structure of
tests. Psychometrika 1951;22:293e6.
12. Kosinski M, Zhao SZ, Dedhiya S, Osterhaus JT, Ware Jr JE.
Determining minimally important changes in generic and
304 J.J. Swigris et al.disease-specific health-related quality of life questionnaires in
clinical trials of rheumatoid arthritis. Arthritis Rheum 2000;
43:1478e87.
13. Kerlinger F. Foundations of behavioral research. New York:
Holt, Rinehart, and Winston; 1973.
14. Witek Jr TJ, Mahler DA. Minimal important difference of the
transition dyspnoea index in a multinational clinical trial. Eur
Respir J 2003;21:267e72.
15. Wyrwich K, Nienaber N, Tierney W, Wolinsky F. Linking clinical
relevance and statistical significance in evaluating intra-indi-
vidual changes in health-related quality of life. Med Care 1999;
37:469e78.
16. Wyrwich K, Tierney W, Wolinsky F. Further evidence supporting
an SEM-based criterion for identifying meaningful intra-indi-
vidual changes in health-related quality of life. J Clin Epi-
demiol 1999;52:861e73.
17. Hays RD, Farivar SS, Liu H. Approaches and recommendations
for estimating minimally important differences for health-
related quality of life measures. COPD 2005;2:63e7.
18. Walters SJ, Brazier JE. What is the relationship between the
minimally important difference and health state utility values?
The case of the SF-6D. Health Qual Life Outcomes 2003;1:4.19. Norman GR, Sloan JA, Wyrwich KW. Interpretation of
changes in health-related quality of life: the remarkable
universality of half a standard deviation. Med Care 2003;
41:582e92.
20. Puhan MA, Frey M, Buchi S, Schunemann HJ. The minimal
important difference of the hospital anxiety and depression
scale in patients with chronic obstructive pulmonary disease.
Health Qual Life Outcomes 2008;6:46.
21. Tomioka H, Imanaka K, Hashimoto K, Iwasaki H. Health-related
qualityof life inpatientswith idiopathicpulmonaryfibrosisecross-
sectional and longitudinal study. Intern Med 2007;46:1533e42.
22. Jones PW. Health status measurement in chronic obstructive
pulmonary disease. Thorax 2001;56:880e7.
23. Jones PW. St. George’s respiratory questionnaire: MCID. COPD
2005;2:75e9.
24. Du Bois RM, Albera C, Costabel U, et al. Categorical declines in
percent predicted forced vital capacity are associated with
a graded risk of death in patients with idiopathic pulmonary
fibrosis. Chest 2008;134:S20003.
25. Zappala C, Latsi P, Nicholson AC, Wells AU. Marginal declines in
FVC levels are associated with increased mortality in idiopathic
pulmonary fibrosis. Thorax 2007;175:A143.
